Beta Bionics Inc

For the period ended Mar 31, 2025. Filed May 6, 2025.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Mar 31, 2025 · Filed May 6, 2025

BBNX$15.70+1.4%Stored close · as of Nov 6, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Financial Statements Condensed Balance Sheets as of March 31, 2025 (Unaudited) and December 31, 2024

CONDENSED BALANCE SHEETS

(In thousands, except number of shares)

	March 31,	December 31,
	2025	2024
(unaudited)
Assets
Current assets:
Cash and cash equivalents	$42,454	$30,432
Short-term investments	189,019	73,143
Accounts receivable, net	9,060	11,996
Inventories, net	15,730	13,320
Prepaid expenses and other current assets	5,652	4,032
Total current assets	261,915	132,923
Property and equipment, net	5,515	4,776
Operating lease right-of-use asset	6,344	6,645
Restricted cash	100	100
Deferred offering costs	—	5,051
Long-term investments	64,004	—
Other long-term assets	146	150
Total assets	$338,024	$149,645
Liabilities, Convertible Preferred Stock and Stockholders’ Equity (Deficit)
Current liabilities:
Accounts payable	$3,454	$2,852
Accrued expenses and other current liabilities	10,565	15,828
Operating lease liabilities	1,524	1,529
Deferred revenue	949	939
Total current liabilities	16,492	21,148
Operating lease liabilities, net of current portion	5,450	5,726
Deferred revenue, net of current portion	2,330	1,860
Warrant liabilities	—	44,898
Total liabilities	24,272	73,632
Commitments and contingencies (Note 17)
Convertible preferred stock (Series A, A-2, B, B-2, C, D and E), par value of $0.0001 per share; no and 34,966,547 shares authorized at March 31, 2025 and December 31, 2024, respectively; no and 17,228,954 shares issued and outstanding at March 31, 2025 and December 31, 2024, respectively; liquidation preference of no and $355,162 at March 31, 2025 and December 31, 2024, respectively	—	321,373
Stockholders’ equity (deficit):
Class A common stock, par value of $0.0001 per share; no and 5,790,000 shares authorized at March 31, 2025 and December 31, 2024, respectively; no and 2,939,085 shares issued and outstanding at March 31, 2025 and December 31, 2024, respectively	—	1
Class B common stock, par value of $0.0001 per share; no and 70,000,000 shares authorized at March 31, 2025 and December 31, 2024, respectively; no and 3,679,790 shares issued and outstanding at March 31, 2025 and December 31, 2024, respectively	—	—
Class C common stock, par value of $0.0001 per share; no and 96,910 shares authorized at March 31, 2025 and December 31, 2024, respectively; no and 48,918 shares issued and outstanding at March 31, 2025 and December 31, 2024, respectively	—	—
Preferred stock, par value of $0.0001 per share; 10,000,000 and no shares authorized at March 31, 2025 and December 31, 2024, respectively; no shares issued or outstanding at March 31, 2025 and December 31, 2024	—	—
Common stock, par value of $0.0001 per share; 700,000,000 and no shares authorized at March 31, 2025 and December 31, 2024, respectively; 43,353,890 and no shares issued and outstanding at March 31, 2025 and December 31, 2024, respectively	4	—
Additional paid-in capital	638,901	51,311
Accumulated other comprehensive income	240	65
Accumulated deficit	(325,393)	(296,737)
Total stockholders’ equity (deficit)	313,752	(245,360)
Total liabilities, convertible preferred stock and stockholders’ equity (deficit)	$338,024	$149,645

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.